Shots: The P-III study involves assessing of larazotide acetate as an adjuvant therapy vs PBO in patients with celiac disease who still experience symptoms despite being on a gluten-free diet […]readmore
Tags : Innovate Biopharmaceuticals
Shots: Innovate Biopharmaceuticals announces the initiation of P-III clinical study of INI-202 for Celiac disease with its expected screening & enrollment updates in next few months The P-III clinical study […]readmore